ZVRA
Zevra Therapeutics, Inc.
Price Chart
Latest Quote
$9.36
Current Price| Previous Close | $9.00 |
| Open | $8.94 |
| Day High | $9.54 |
| Day Low | $8.87 |
| Volume | 1,056,707 |
Stock Information
| Shares Outstanding | 56.30M |
| Total Debt | $62.72M |
| Cash Equivalents | $199.51M |
| Revenue | $84.39M |
| Net Income | $30.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $526.94M |
| P/E Ratio | 19.91 |
| EPS (TTM) | $0.47 |
| Exchange | NMS |
đ Custom Metrics & Score
Score: 6/42| Debt to Equity | 1.52 |
| Debt to Earnings | 3.72 |
| Current Ratio | 2.53 |
| Quick Ratio | 2.35 |
| Avg Revenue Growth | -4.40% |
| Profit Margin | -446.85% |
| Return on Equity | -266.00% |
| Avg FCF Growth | -193.48% |
| FCF Yield | -13.22% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $9.36 | 1,064,116 |
| 2026-01-30 | $9.00 | 715,100 |
| 2026-01-29 | $8.86 | 733,500 |
| 2026-01-28 | $8.63 | 1,524,300 |
| 2026-01-27 | $8.93 | 635,400 |
| 2026-01-26 | $9.02 | 847,300 |
| 2026-01-23 | $8.97 | 1,449,000 |
| 2026-01-22 | $9.08 | 1,343,500 |
| 2026-01-21 | $9.03 | 958,100 |
| 2026-01-20 | $9.02 | 860,900 |
| 2026-01-16 | $8.93 | 746,700 |
| 2026-01-15 | $9.02 | 1,890,800 |
| 2026-01-14 | $9.17 | 1,091,900 |
| 2026-01-13 | $8.92 | 1,959,100 |
| 2026-01-12 | $8.38 | 1,002,300 |
| 2026-01-09 | $8.49 | 771,900 |
| 2026-01-08 | $8.63 | 741,000 |
| 2026-01-07 | $8.48 | 893,000 |
| 2026-01-06 | $8.31 | 803,400 |
| 2026-01-05 | $8.34 | 849,200 |
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
đ° Latest News
Investing in Zevra Therapeutics (NASDAQ:ZVRA) three years ago would have delivered you a 63% gain
Simply Wall St. âĸ 2026-01-24T12:42:41Z
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away
Motley Fool âĸ 2025-12-28T17:46:46Z
Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress?
Simply Wall St. âĸ 2025-12-14T10:04:27Z
Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback?
Simply Wall St. âĸ 2025-12-14T04:07:29Z
Analysts Have Lowered Expectations For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Latest Results
Simply Wall St. âĸ 2025-11-08T14:15:36Z
Zevra Therapeutics Inc (ZVRA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
GuruFocus.com âĸ 2025-11-06T05:03:34Z
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-05T22:50:03Z
Zevra Therapeutics: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-05T21:48:09ZZevra Therapeutics, Inc. (NASDAQ:ZVRA) is definitely on the radar of institutional investors who own 50% of the company
Simply Wall St. âĸ 2025-10-30T11:22:49Z
Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains?
Zacks âĸ 2025-10-16T12:55:00Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $7,263,000 | $1,939,000 | $222,000 | $2,059,000 |
| Cost Of Revenue | $7,417,000 | $2,173,000 | $222,000 | $2,059,000 |
| Total Revenue | $23,612,000 | $27,461,000 | $10,161,000 | $28,650,000 |
| Operating Revenue | $23,612,000 | $27,461,000 | $10,161,000 | $28,650,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $7,351,000 | $1,501,000 | $335,000 | $376,000 |
| Total Expenses | $110,615,000 | $77,065,000 | $35,063,000 | $20,921,000 |
| Other Income Expense | $2,039,000 | $515,000 | $-3,081,000 | $-16,135,000 |
| Net Non Operating Interest Income Expense | $-5,176,000 | $3,040,000 | $1,178,000 | $-115,000 |
| Interest Expense Non Operating | $7,351,000 | $1,501,000 | $335,000 | $376,000 |
| Operating Expense | $103,198,000 | $74,892,000 | $34,841,000 | $18,862,000 |
| General And Administrative Expense | - | - | $15,343,000 | $8,701,000 |
| Total Other Finance Cost | - | - | - | $150,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-105,511,000 | $-46,049,000 | $-26,772,000 | $-8,555,000 |
| Net Interest Income | $-5,176,000 | $3,040,000 | $1,178,000 | $-115,000 |
| Interest Income | $2,175,000 | $4,541,000 | $1,513,000 | $261,000 |
| Normalized Income | $-107,121,810 | $-46,564,000 | $-23,694,697 | $3,223,550 |
| Net Income From Continuing And Discontinued Operation | $-105,511,000 | $-46,049,000 | $-26,772,000 | $-8,555,000 |
| Total Operating Income As Reported | $-87,003,000 | $-49,604,000 | $-42,565,000 | $7,729,000 |
| Net Income Common Stockholders | $-105,511,000 | $-46,049,000 | $-26,772,000 | $-62,897,000 |
| Net Income | $-105,511,000 | $-46,049,000 | $-26,772,000 | $-8,555,000 |
| Net Income Including Noncontrolling Interests | $-105,511,000 | $-46,049,000 | $-26,772,000 | $-8,555,000 |
| Net Income Continuous Operations | $-105,511,000 | $-46,049,000 | $-26,772,000 | $-8,555,000 |
| Pretax Income | $-90,140,000 | $-46,049,000 | $-26,805,000 | $-8,521,000 |
| Interest Income Non Operating | $2,175,000 | $4,541,000 | $1,513,000 | $261,000 |
| Operating Income | $-87,003,000 | $-49,604,000 | $-24,902,000 | $7,729,000 |
| Depreciation Amortization Depletion Income Statement | $6,235,000 | $772,000 | - | - |
| Depreciation And Amortization In Income Statement | $6,235,000 | $772,000 | - | - |
| Amortization Of Intangibles Income Statement | $6,235,000 | $772,000 | - | - |
| Gross Profit | $16,195,000 | $25,288,000 | $9,939,000 | $26,591,000 |
| Special Income Charges | - | $0 | $-17,663,000 | $-16,096,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.28 | $-1.30 | $-1.20 | $-2.11 |
| Basic EPS | $-2.28 | $-1.30 | $-1.20 | $-2.11 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $428,190 | $0 | $-3,697 | $-4,356,450 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-78,439,000 | $-44,057,000 | $-22,445,000 | $8,247,000 |
| Total Unusual Items | $2,039,000 | $515,000 | $-3,081,000 | $-16,135,000 |
| Total Unusual Items Excluding Goodwill | $2,039,000 | $515,000 | $-3,081,000 | $-16,135,000 |
| Reconciled Depreciation | $6,389,000 | $1,006,000 | $944,000 | $257,000 |
| EBITDA (Bullshit earnings) | $-76,400,000 | $-43,542,000 | $-25,526,000 | $-7,888,000 |
| EBIT | $-82,789,000 | $-44,548,000 | $-26,470,000 | $-8,145,000 |
| Diluted Average Shares | $46,251,239 | $35,452,460 | $34,488,800 | $29,766,347 |
| Basic Average Shares | $46,251,239 | $35,452,460 | $34,488,800 | $29,766,347 |
| Diluted NI Availto Com Stockholders | $-105,511,000 | $-46,049,000 | $-26,772,000 | $-62,897,000 |
| Tax Provision | $15,371,000 | $0 | $-33,000 | $34,000 |
| Gain On Sale Of Security | $2,039,000 | $515,000 | $14,582,000 | $-39,000 |
| Amortization | $6,235,000 | $772,000 | - | - |
| Research And Development | $42,095,000 | $39,806,000 | $19,803,000 | $10,161,000 |
| Selling General And Administration | $54,868,000 | $34,314,000 | $15,038,000 | $8,701,000 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $54,342,000 |
| Other Special Charges | - | - | $17,663,000 | $16,096,000 |
| Other Gand A | - | - | $15,343,000 | $8,701,000 |
| Restructuring And Mergern Acquisition | - | - | - | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-34,028,000 | $-12,064,000 | $75,120,000 | $127,118,000 |
| Total Assets | $178,127,000 | $172,327,000 | $115,340,000 | $132,941,000 |
| Total Non Current Assets | $92,100,000 | $85,389,000 | $22,506,000 | $17,885,000 |
| Other Non Current Assets | $11,383,000 | $9,935,000 | $724,000 | $438,000 |
| Investmentin Financial Assets | $6,010,000 | $0 | $0 | $14,932,000 |
| Goodwill And Other Intangible Assets | $73,694,000 | $73,928,000 | $0 | - |
| Other Intangible Assets | $68,993,000 | $69,227,000 | - | - |
| Current Assets | $86,027,000 | $86,938,000 | $92,834,000 | $115,056,000 |
| Other Current Assets | $3,015,000 | $652,000 | $1,111,000 | $252,000 |
| Prepaid Assets | $1,037,000 | $1,172,000 | $577,000 | $930,000 |
| Inventory | $1,970,000 | $0 | - | - |
| Receivables | $10,509,000 | $17,377,000 | $8,299,000 | $1,528,000 |
| Other Receivables | $333,000 | $1,258,000 | $1,114,000 | $107,000 |
| Accounts Receivable | $10,176,000 | $16,119,000 | $7,185,000 | $1,421,000 |
| Cash Cash Equivalents And Short Term Investments | $69,496,000 | $67,737,000 | $82,847,000 | $112,346,000 |
| Cash And Cash Equivalents | $33,785,000 | $43,049,000 | $65,466,000 | $112,346,000 |
| Restricted Cash | - | - | - | $0 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $25,719,000 | - | - | - |
| Total Debt | $60,296,000 | $43,765,000 | $14,123,000 | $1,609,000 |
| Long Term Debt And Capital Lease Obligation | $59,876,000 | $5,522,000 | $13,643,000 | $1,238,000 |
| Long Term Debt | $59,504,000 | $5,066,000 | $12,800,000 | - |
| Current Debt And Capital Lease Obligation | $420,000 | $38,243,000 | $480,000 | $371,000 |
| Current Debt | - | $37,700,000 | $4,655,000 | - |
| Other Current Borrowings | - | $37,700,000 | $4,655,000 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $138,461,000 | $110,463,000 | $40,220,000 | $5,823,000 |
| Total Non Current Liabilities Net Minority Interest | $104,396,000 | $36,743,000 | $28,197,000 | $1,593,000 |
| Other Non Current Liabilities | $12,285,000 | $15,121,000 | $4,352,000 | $25,000 |
| Derivative Product Liabilities | $17,804,000 | $16,100,000 | $10,202,000 | $330,000 |
| Tradeand Other Payables Non Current | $14,431,000 | $0 | - | - |
| Current Liabilities | $34,065,000 | $73,720,000 | $12,023,000 | $4,230,000 |
| Other Current Liabilities | $8,189,000 | $7,074,000 | $5,374,000 | $821,000 |
| Payables And Accrued Expenses | $25,456,000 | $28,403,000 | $6,169,000 | $3,038,000 |
| Payables | $13,075,000 | $13,987,000 | $3,611,000 | $516,000 |
| Accounts Payable | $13,075,000 | $13,987,000 | $3,611,000 | $516,000 |
| Interest Payable | - | - | - | $0 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $39,666,000 | $61,864,000 | $75,120,000 | $127,118,000 |
| Total Equity Gross Minority Interest | $39,666,000 | $61,864,000 | $75,120,000 | $127,118,000 |
| Stockholders Equity | $39,666,000 | $61,864,000 | $75,120,000 | $127,118,000 |
| Gains Losses Not Affecting Retained Earnings | $631,000 | $-43,000 | $113,000 | $0 |
| Other Equity Adjustments | $631,000 | $-43,000 | $113,000 | - |
| Retained Earnings | $-505,289,000 | $-399,778,000 | $-353,729,000 | $-267,029,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $1,575,692 | $1,575,692 | $909,953 | $320,161 |
| Ordinary Shares Number | $53,670,709 | $41,534,668 | $34,540,304 | $35,005,640 |
| Share Issued | $55,246,401 | $43,110,360 | $35,450,257 | $35,325,801 |
| Tangible Book Value | $-34,028,000 | $-12,064,000 | $75,120,000 | $127,118,000 |
| Invested Capital | $99,170,000 | $104,630,000 | $87,920,000 | $127,118,000 |
| Working Capital | $51,962,000 | $13,218,000 | $80,811,000 | $110,826,000 |
| Capital Lease Obligations | $792,000 | $999,000 | $1,323,000 | $1,609,000 |
| Total Capitalization | $99,170,000 | $66,930,000 | $87,920,000 | $127,118,000 |
| Treasury Stock | $10,983,000 | $10,983,000 | $7,536,000 | $2,814,000 |
| Additional Paid In Capital | $555,302,000 | $472,664,000 | $436,269,000 | $396,957,000 |
| Capital Stock | $5,000 | $4,000 | $3,000 | $4,000 |
| Common Stock | $5,000 | $4,000 | $3,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $372,000 | $456,000 | $843,000 | $1,238,000 |
| Current Capital Lease Obligation | $420,000 | $543,000 | $480,000 | $371,000 |
| Current Accrued Expenses | $12,381,000 | $14,416,000 | $2,558,000 | $2,522,000 |
| Investments And Advances | $6,010,000 | $0 | $20,000,000 | $15,422,000 |
| Available For Sale Securities | $6,010,000 | - | - | $14,932,000 |
| Goodwill | $4,701,000 | $4,701,000 | $0 | - |
| Net PPE | $1,013,000 | $1,526,000 | $1,782,000 | $2,025,000 |
| Accumulated Depreciation | $-1,726,000 | $-1,634,000 | $-1,443,000 | $-1,925,000 |
| Gross PPE | $2,739,000 | $3,160,000 | $3,225,000 | $3,950,000 |
| Leases | $710,000 | $710,000 | $710,000 | $724,000 |
| Other Properties | $1,128,000 | $1,650,000 | $1,949,000 | $2,817,000 |
| Machinery Furniture Equipment | $901,000 | $800,000 | $566,000 | $409,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $35,711,000 | $24,688,000 | $17,381,000 | $0 |
| Other Investments | - | - | $20,000,000 | $490,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-69,665,000 | $-33,831,000 | $-18,810,000 | $10,337,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-69,665,000 | $-33,535,000 | $-18,717,000 | $10,439,000 |
| Cash Flow From Continuing Operating Activities | $-69,665,000 | $-33,535,000 | $-18,717,000 | $10,439,000 |
| Operating Gains Losses | $-1,620,000 | $57,000 | $-15,241,000 | $16,198,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Investing Cash Flow | $-22,161,000 | $-17,390,000 | $-36,719,000 | $-15,524,000 |
| Cash Flow From Continuing Investing Activities | $-22,161,000 | $-17,390,000 | $-36,719,000 | $-15,524,000 |
| Net Other Investing Changes | $-6,000,000 | - | - | - |
| Capital Expenditure | - | $-296,000 | $-93,000 | $-102,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $0 | $-3,447,000 | $-4,723,000 | $-2,814,000 |
| Issuance Of Capital Stock | $64,516,000 | $6,106,000 | $0 | $49,285,000 |
| Financing Cash Flow | $82,108,000 | $28,464,000 | $8,352,000 | $113,109,000 |
| Cash Flow From Continuing Financing Activities | $82,108,000 | $28,464,000 | $8,352,000 | $113,109,000 |
| Net Other Financing Charges | $-1,440,000 | $692,000 | $-33,000 | $73,916,000 |
| Net Common Stock Issuance | $64,516,000 | $2,659,000 | $-4,723,000 | $46,471,000 |
| Common Stock Issuance | $64,516,000 | $6,106,000 | $0 | $49,285,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-42,700,000 | $-17,536,000 | $-16,000 | $-38,097,000 |
| Issuance Of Debt | $58,990,000 | $42,431,000 | $12,800,000 | $0 |
| Interest Paid Supplemental Data | $5,262,000 | $456,000 | $321,000 | $218,000 |
| End Cash Position | $33,785,000 | $43,049,000 | $65,466,000 | $112,346,000 |
| Beginning Cash Position | $43,049,000 | $65,466,000 | $112,346,000 | $4,322,000 |
| Effect Of Exchange Rate Changes | $454,000 | $44,000 | $204,000 | $0 |
| Changes In Cash | $-9,718,000 | $-22,461,000 | $-47,084,000 | $108,024,000 |
| Proceeds From Stock Option Exercised | $2,742,000 | $218,000 | $324,000 | $30,819,000 |
| Common Stock Payments | $0 | $-3,447,000 | $-4,723,000 | $-2,814,000 |
| Net Issuance Payments Of Debt | $16,290,000 | $24,895,000 | $12,784,000 | $-38,097,000 |
| Net Long Term Debt Issuance | $16,290,000 | $24,895,000 | $12,784,000 | $-38,097,000 |
| Long Term Debt Payments | $-42,700,000 | $-17,536,000 | $-16,000 | $-38,097,000 |
| Long Term Debt Issuance | $58,990,000 | $42,431,000 | $12,800,000 | $0 |
| Net Investment Purchase And Sale | $-16,161,000 | $13,307,000 | $-22,536,000 | $-15,422,000 |
| Sale Of Investment | $25,000,000 | $59,121,000 | $1,325,000 | - |
| Purchase Of Investment | $-41,161,000 | $-45,814,000 | $-23,861,000 | $-15,422,000 |
| Net Business Purchase And Sale | $0 | $-30,401,000 | $-14,090,000 | $0 |
| Purchase Of Business | $0 | $-30,401,000 | $-14,090,000 | $0 |
| Net PPE Purchase And Sale | $0 | $-296,000 | $-93,000 | $-102,000 |
| Purchase Of PPE | $0 | $-296,000 | $-93,000 | $-102,000 |
| Change In Working Capital | $-6,640,000 | $5,883,000 | $-406,000 | $-357,000 |
| Change In Other Working Capital | $431,000 | $3,231,000 | $3,782,000 | - |
| Change In Other Current Liabilities | $209,000 | $-79,000 | $-463,000 | $397,000 |
| Change In Other Current Assets | $552,000 | $321,000 | $663,000 | $133,000 |
| Change In Payables And Accrued Expense | $-3,598,000 | $11,130,000 | $3,131,000 | $-1,113,000 |
| Change In Prepaid Assets | $-2,228,000 | $152,000 | $-894,000 | $-825,000 |
| Change In Inventory | $-8,874,000 | $206,000 | $147,000 | $0 |
| Change In Receivables | $6,868,000 | $-9,078,000 | $-6,772,000 | $1,051,000 |
| Other Non Cash Items | $2,563,000 | $227,000 | $17,887,000 | $460,000 |
| Stock Based Compensation | $14,906,000 | $5,954,000 | $4,294,000 | $2,436,000 |
| Unrealized Gain Loss On Investment Securities | $18,000 | $-613,000 | $577,000 | $0 |
| Provisionand Write Offof Assets | $5,746,000 | $0 | - | - |
| Amortization Of Securities | $-890,000 | $0 | - | - |
| Deferred Tax | $15,374,000 | $0 | - | - |
| Deferred Income Tax | $15,374,000 | $0 | - | - |
| Depreciation Amortization Depletion | $6,389,000 | $1,006,000 | $944,000 | $257,000 |
| Depreciation And Amortization | $6,389,000 | $1,006,000 | $944,000 | $257,000 |
| Gain Loss On Investment Securities | $-2,057,000 | $98,000 | $-15,159,000 | $26,000 |
| Net Foreign Currency Exchange Gain Loss | $219,000 | $-198,000 | $-91,000 | $0 |
| Gain Loss On Sale Of PPE | $218,000 | $157,000 | $9,000 | $76,000 |
| Net Income From Continuing Operations | $-105,511,000 | $-46,049,000 | $-26,772,000 | $-8,555,000 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |